Leukemias

Most recent

APL in the obese: Should we treat it differently?

Jitani AK, et al. APL 2017:PO031 Background Differentiation syndrome (DS) is a life-threatening complication in acute promyelocytic leukemia (APL). Studies have reported that a high body mass index (BMI) is the most powerful predictor of DS, with an odds ratio of...

Front-line therapy of APL: Randomized comparison of ATRA and intensified chemotherapy including high dose cytosine-arabinoside versus ATRA and anthracyclines — a prospective, multicentre, randomized clinical trial of the German Acute Myeloid Leukemia Cooperative Group

Lengfelder E, et al. APL 2017:CO027 Background The APL-2005 study was started as an Acute Myeloid Leukemia Cooperative Group (AMLCG) trial with the intention to be part of an acute promyelocytic leukemia (APL) intergroup study with the PETHEMA LPA99 protocol as a...

Other

Summary of Session X at the 7th International Symposium on APL

Clinical trial updates in the treatment of APL At the 7th International Symposium on APL, Dr. Harry Iland, Dr. Vikram Mathews, and Dr. Nigel Russell presented updates from clinical trials involving the incorporation of arsenic trioxide (ATO) in front-line and relapsed...

Real-life experience with ATRA and ATO-based regimens in APL

Platzbecker U, et al. APL 2017:PO027bis Background In the APL0406 trial, the combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) was shown to be superior to standard ATRA and chemotherapy in front-line therapy for patients with low- to...

A Summary of Session VII at the 2017 International Symposium on APL

Early Death and Population-Based Studies in APL At the 2017 International Symposium on APL, Dr. Matthew Seftel, Dr. Anand Jillella, and Dr. Soren Lehmann gave presentations on observational studies in acute promyelocytic leukemia (APL), with a particular emphasis on...

A Canadian Perspective on APL Treatment by Dr. Matthew Seftel

Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) characterized by the promyelocytic leukemia-retinoic acid receptor alpha (PML-RARα) translocation between chromosomes 15 and 17. Historically, the combination of all-trans retinoic...

Twitter feed

Already looking forward to #ASH19 ? The NE Live Team has you covered until then. Catch up on perspectives captured… https://t.co/TPVZDwe1nc
h J R
Unable to attend #ASH18 ? NE Live was on site to capture up-to-the-minute perspectives on pivitol research. Visit… https://t.co/hyGWk82vqo
h J R
Watch the NE Live team discuss The GRIFFIN Study in Patients with Newly Diagnosed Multiple Myeloma Eligible for HDT… https://t.co/bIY5TzmT9L
h J R
The NE Live team caught up with Dr. Laurie Sehn on day 2 of #ASH18 to discuss The AUGMENT Study with Lenalidomide a… https://t.co/vE7NnCBL40
h J R